BRIEF-Takeda Strengthens Oncology Pipeline With Elritercept Through Licensing Agreement With Keros Therapeutics

Reuters
03 Dec 2024

Dec 3 (Reuters) - Takeda Pharmaceutical :

* TAKEDA STRENGTHENS ONCOLOGY PIPELINE WITH ELRITERCEPT THROUGH LICENSING AGREEMENT WITH KEROS THERAPEUTICS

* TAKEDA PHARMACEUTICAL CO LTD - TAKEDA TO RECEIVE EXCLUSIVE GLOBAL LICENSE IN ALL TERRITORIES OUTSIDE OF MAINLAND CHINA, HONG KONG AND MACAU

* TAKEDA PHARMACEUTICAL CO LTD - TO PAY KEROS THERAPEUTICS $200 MILLION UPFRONT

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10